

## **Adult CIRB - Early Phase Emphasis Meeting Agenda**

**June 17, 2025**

---

### **I New Study - Initial Review**

**10660**, A Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of Sotorasib Plus Trastuzumab Deruxtecan in Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation (Version Date 04/17/25)

---

### **II New Study - Initial Review**

**10702**, A Phase II Study of Glofitamab for Relapsed/Refractory Mantle Cell Lymphoma in Patients Previously Treated with CD19-directed CAR T-cell Therapy (Version Date 04/30/25)

---

### **III Continuing Review**

**10411**, Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients with Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-deficient Gastrointestinal Stromal Tumor (GIST) (Version Date 04/04/25)

---

### **IV Continuing Review**

**EAY191-N4**, Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial (Version Date 05/13/25)

---

### **V Continuing Review**

**A051901**, Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (NIVO-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma (Version Date 03/21/25)

---